Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 113 matches for

EMPA-KIDNEY is a clinical trial testing whether taking a single pill of empagliflozin every day prevents worsening of kidney disease or deaths from heart disease in people who have chronic kidney disease.

News

Frequently Asked Questions

This information is for people in the UK. These are questions that you might have about the EMPA-KIDNEY Study (the Study of Heart and Kidney Protection with Empagliflozin). You can also download a copy of the Participant Information Leaflet and other study documents from the Downloads section.

Our Team

Downloads

Download EMPA-KIDNEY study documents (for UK participants unless stated otherwise)

Files library

Forms library

About us

Appropriately initiate 24/365 core competencies after resource-leveling partnerships. Authoritatively initiate clicks-and-mortar metrics rather than parallel potentialities.